AstraZeneca's Lynparza meets main goal in late-stage prostate cancer study

British drugmaker AstraZeneca said on Wednesday its cancer drug Lynparza has met the main goal of a late-stage study in patients with metastatic prostate cancer and have certain genetic mutations.